- Home
- INSM vs ARE Comparison
INSM vs ARE Comparison
Compare INSM & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- ARE
- Stock Information
- Founded
- INSM 1988
- ARE 1994
- Country
- INSM United States
- ARE United States
- Employees
- INSM N/A
- ARE N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- ARE Real Estate Investment Trusts
- Sector
- INSM Health Care
- ARE Real Estate
- Exchange
- INSM Nasdaq
- ARE Nasdaq
- Market Cap
- INSM 12.6B
- ARE 13.3B
- IPO Year
- INSM 2000
- ARE 1997
- Fundamental
- Price
- INSM $65.08
- ARE $74.07
- Analyst Decision
- INSM Strong Buy
- ARE Hold
- Analyst Count
- INSM 16
- ARE 9
- Target Price
- INSM $95.36
- ARE $120.00
- AVG Volume (30 Days)
- INSM 2.5M
- ARE 1.7M
- Earning Date
- INSM 05-08-2025
- ARE 04-28-2025
- Dividend Yield
- INSM N/A
- ARE 7.13%
- EPS Growth
- INSM N/A
- ARE N/A
- EPS
- INSM N/A
- ARE 0.76
- Revenue
- INSM $381,030,000.00
- ARE $3,111,841,000.00
- Revenue This Year
- INSM $30.36
- ARE N/A
- Revenue Next Year
- INSM $115.55
- ARE $3.84
- P/E Ratio
- INSM N/A
- ARE $97.12
- Revenue Growth
- INSM 20.77
- ARE 5.31
- 52 Week Low
- INSM $21.92
- ARE $70.57
- 52 Week High
- INSM $84.91
- ARE $130.14
- Technical
- Relative Strength Index (RSI)
- INSM 35.80
- ARE 39.20
- Support Level
- INSM $63.81
- ARE $71.35
- Resistance Level
- INSM $73.39
- ARE $74.72
- Average True Range (ATR)
- INSM 2.53
- ARE 2.14
- MACD
- INSM -0.38
- ARE 0.55
- Stochastic Oscillator
- INSM 13.26
- ARE 36.92
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.